scholarly journals Pharmacotherapeutic efficiency and advantages of the combined treatment of patients with type 2 diabetes mellitus

2017 ◽  
Vol 13 (6) ◽  
pp. 435-439
Author(s):  
V.I. Pankiv
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Combined Treatment

scholarly journals Prevalence of Anaemia and Its Associated Factors among Type 2 Diabetes Mellitus Patients in University of Gondar Comprehensive Specialized Hospital

Anemia ◽  
2021 ◽  
Vol 2021 ◽  
pp. 1-5
Author(s):  
Sewnet Adem Kebede ◽  
Biruk Shalmeno Tusa ◽  
Adisu Birhanu Weldesenbet
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Associated Factors ◽  
Microvascular Complications ◽  
Combined Treatment ◽  
Factors Associated ◽  
Specialized Hospital ◽  
Patients With Diabetes

Background. Anaemia is one of the commonest blood disorders seen in patients with diabetes. In Ethiopia, chronic illnesses are tremendously raising with their complications. But very little research has been conducted, particularly on anaemia among diabetes mellitus (DM) patients. Therefore, this study aimed at assessing the prevalence of anaemia and associated factors among type 2 diabetes mellitus patients in Northwest Ethiopia. Methods. A cross-sectional study design was employed at University of Gondar Comprehensive Specialized Hospital from March 1 to April 15, 2019, among 372 type 2 diabetes mellitus patients (T2DM). Multivariable logistic regression analysis was fitted, and the corresponding adjusted odds ratio (AOR) and 95% CI were used to identify factors associated with anaemia. Level of significance was declared at the p value less than 0.05. Results. The study revealed 8.06% (95% CI: 5.68–11.31%) of the participants were anaemic. Being male (AOR = 2.74, CI: 1.02, 7.38), combined type of treatment (AOR = 8.38, CI: 1.66, 42.25), having diabetes-related microvascular complications (AOR = 3.24, CI: 1.14, 9.26), and hypertension (AOR = 0.01, CI: 0.002, 0.06) were the significant factors associated with anaemia. Conclusions. The finding of the current study revealed low prevalence of anaemia among T2DM patients. Sex, type of treatment, diabetes-related microvascular complications, and hypertension were factors associated with anaemia. Assessment of haemoglobin levels among T2DM patients may help to prevent ensuing microvascular complications. Incorporate anaemia screening into the routine assessment of diabetic complication particularly for those who are hypertensive and took combined treatment to allow early appreciation and treatment of anaemia and later improve the overall care of patients with diabetes.

Efficacy and tolerability of combined treatment with l-carnitine and simvastatin in lowering lipoprotein(a) serum levels in patients with type 2 diabetes mellitus

2006 ◽  
Vol 188 (2) ◽  
pp. 455-461 ◽  
Author(s):  
Vincenzo Solfrizzi ◽  
Cristiano Capurso ◽  
Anna M. Colacicco ◽  
Alessia D’Introno ◽  
Cristina Fontana ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Combined Treatment ◽  
Serum Levels ◽  
Lipoprotein A

scholarly journals Efficacy of combined treatment of distal polyneuropathy in patients with type 2 diabetes mellitus and concomitant primaryhypothyroidism

2011 ◽  
Vol 14 (3) ◽  
pp. 76-79
Author(s):  
Inessa Ivanovna Dubinina ◽  
Tatiana Vladimirovna Karapysh ◽  
Nina Fedorovna Nosova
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Combined Therapy ◽  
Combined Treatment ◽  
Metabolic Parameters ◽  
Postprandial Glycemia ◽  
Thyroid Pathology ◽  
Hba1c Levels

Aim. To study changes of metabolic parameters and neurologic manifestations in patients with type 2 diabetes mellitus and concomitant primaryhypothyroidism under effect of combined therapy. Materials and methods. 62 patients with distal neuropathy (DN) including 16 with DM2 and primary hypothyroidism (PHT) (group 1), 32 DM2patients without thyroid pathology (group 2), and 15 patients with PHT without DM (group 3). The patients were matched for age and durationof all above diseases. They were treated by alpha lipoic acid-based drugs: thioctacid, thiogamma, berlithion, octolipen (600 U/d i/v), vitamins B:milgamma, combilipen (2 ml/d i/m) for 12 weeks. All measurements were made at admittance, 21 days and 12 weeks after it. The efficacy of therapywas estimated from changes in HbA1c levels, fasting and postprandial glycemia, lipid metabolism. DN was diagnosed using NSS, TSS, NDS, NDSm,and NIS-LL scales. Results. Combined therapy of patients with DM2 and PHT resulted in a decrease of HbA1c levels within 12 weeks, fasting and postprandialglycemia within 21 and 12 weeks respectively. Compensation of PHT led to a decrease of total cholesterol and triglyceride levels within 12 weeks.Subcompensation of carbohydrate metabolism (postprandial glycemia) improved neurologic symptoms within 21 weeks in all patients (NSS and TSSscales). The same effect was documented within 12 weeks in patients without thyroid pathology (NSS, TSS, NDS, NDSm, and NIS-LL scales). Inthose with PHT beneficial effect was revealed only using the NIS-LL scale. The worst outcome of therapy estimated from NSS, TSS, NDS, NDSm,and NIS-LL scales was documented in patients with DM2+PHT probably due to additional effect of thyroid pathology on the severity of DN. Conclusion. The use of NSS, TSS, NDS, NDSm, and NIS-LL scales makes it possible to reveal changes in the severity of sensorimotor disturbancesin DN patients depending on metabolic parameters modified by pathogenetic therapy.

scholarly journals Clinician prescription of lipid-lowering drugs and achievement of treatment goals in patients with newly diagnosed type 2 diabetes mellitus

2021 ◽  
Vol 9 (1) ◽  
pp. e001891
Author(s):  
Ana Cristina García-Ulloa ◽  
Claudia Lechuga-Fonseca ◽  
Fabiola Mabel Del Razo-Olvera ◽  
Carlos Alberto Aguilar-Salinas ◽  
Karla Ivette Galaviz ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Myocardial Infarct ◽  
Combined Treatment ◽  
Real Life ◽  
Lipid Lowering ◽  
Moderate Intensity ◽  
Lipid Lowering Drugs

IntroductionLipid control is essential in type 2 diabetes mellitus (T2DM). The aim of this study is to investigate factors associated with lipid therapy adherence and achievement of goals in real-life setting among patients with recently diagnosed T2DM.Research design and methodsThis is a longitudinal analysis in a center of comprehensive care for patients with diabetes. We include patients with T2DM, <5 years of diagnosis, without disabling complications (eg, amputation, myocardial infarct, stroke, proliferative retinopathy, glomerular filtration rate <60 mL/min/m2) and completed 2-year follow-up. The comprehensive diabetes care model includes 9 interventions in 4 initial visits and annual evaluations. Endocrinologists follow the clinic’s guideline and adapt therapy to reach risk-based treatment goal. The main outcome measures were the proportion of patients meeting low-density lipoprotein cholesterol (c-LDL) (<100 mg/dL) and triglycerides (<150 mg/dL) and proportion of patients taking statin, fibrate or combination at baseline, 3 months and annual evaluations.ResultsWe included 288 consecutive patients (54±9 years, 53.8% women), time since T2DM diagnosis 1 (0–5) year. Baseline, 10.8% patients were receiving statin therapy (46.5% moderate-intensity therapy and 4.6% high-intensity therapy), 8.3% fibrates and 4.2% combined treatment. The proportion of patients with combined treatment increased to 41.6% at 3 months, decreased to 20.8% at 1 year and increased to 38.9% at 2 years of evaluation. Patients receiving treatment met LDL and triglycerides goals at 3 months (17% vs 59.7%, relative ratio (RR)=0.89, 95% CI 0.71 to 1.12), at 1 year (17% vs 26.7%, RR=0.62, 95% CI 0.41 to 0.95) and at 2 years (17% vs 29.9%, RR=0.63, 95% CI 0.43 to 0.93). Main reasons for medication suspension: patient considered treatment was not important (37.5%) and other physician suspended treatment (31.3%).Conclusion88.2% of patients with T2DM required lipid-lowering drugs. Education for patients and physicians is critical to achieve and maintain diabetes goals.Trial registration numberNCT02836808.

scholarly journals The results of DINASTIYA study - Diabeton MB: the observational program among the patients with type 2 diabetes mellitus under conditions of routine clinical practice

2012 ◽  
Vol 58 (5) ◽  
pp. 28-36
Author(s):  
M V Shestakova ◽  
O K Vikulova ◽  
D A Avaliani ◽  
S N Avdeeva ◽  
G P Aĭdinian ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Clinical Practice ◽  
Glycemic Control ◽  
Combined Treatment ◽  
Routine Clinical Practice ◽  
The Body ◽  
Daily Dose

The aim of the DINASTIYA study (the name of this study is the acronym composed of the selected letters from the Russian title: "DIabeton MB - Nablyudatel'naya programma sredi patsientov c Sakharnym diabeTom 2 tipa v uslovIYAkh rutinnoy praktiki") was to estimate the possibility of achieving the targeted parameters of glycemic control by means of the step by step increase of diabeton MB dose and to evaluate the safety of this therapy under conditions of routine clinical practice. Materials and methods: The program involved 2213 patients with poorly controlled type 2 diabetes mellitus who had been treated with diabeton MB during the preceding period (30-90 mg/day in the form of monotherapy or in combination with the maximum tolerated dose of metformin). The dose of diabeton MB was titrated under control of glycemia during 3 months. The combined treatment including metformin was given to 70% of the patients. The average daily dose of diabeton MB by the end of the study was 90.9 mg. As many as 70% of the petients received diabeton MB at a daily dose of 90-120 mg. Results: The statistically significant reduction of the fasting blood glucose (FG) level from 8.3±1.6 mmol/l to 6.2±0.9 mmol/l and postprandial glycemia (PPG) from 10.5±2.1 mmol/l to 7.6±1.0 mmol/l was documented within 3 month after the onset of therapy. The targeted FG and PPG levels (<6.5 mmol/l and <8.0 mmol/l) were achieved in 68.9% and 71.5% of the patients respectively. Simultaneously, the body weight decreased (by 1 kg on the average) and arterial pressure fell down (SAP - 8.4 and DAP - 3.9 mm HG respectively). Conclusion: The strategy of management of type 2 diabetes mellitus based on the step by step increase of the dose of diabeton MB allows the targeted parameters of glycemic control to be achieved in combination with the good tolerability of the treatment and the low risk of development of hypoglycemia.

scholarly journals Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program

2010 ◽  
Vol 13 (3) ◽  
pp. 57-60 ◽  
Author(s):  
Marina Vladimirovna Shestakova
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Hba1c Level ◽  
Combined Treatment ◽  
Efficacy And Safety ◽  
Metformin Monotherapy ◽  
Observation Program ◽  
The Russian Federation

This paper reports results of the DIA-DA observation program designed to study the efficacy and safety of the DPP-4 inhibitor sitagliptin added tometformin therapy in different regions of the Russian Federation. The study included 923 patients with DM2 (mean duration 4.5 years) uncontrolledby diet and metformin monotherapy. They were transferred to the combined treatment with sitagliptin and metformin during 6 months. The mainend-points assessed in the study were hypoglycemic efficiency, frequency of side-effects, and satisfaction of patients and physicians with the treatment.The target HbA1c level

Combined Treatment of Intrapancreatic Autologous Bone Marrow Stem Cells and Hyperbaric Oxygen in Type 2 Diabetes Mellitus

2008 ◽  
Vol 17 (12) ◽  
pp. 1295-1304 ◽  
Author(s):  
Esteban J. Estrada ◽  
Fabian Valacchi ◽  
Eduardo Nicora ◽  
Sergio Brieva ◽  
Claudio Esteve ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Stem Cells ◽  
Bone Marrow ◽  
Type 2 Diabetes Mellitus ◽  
Hyperbaric Oxygen ◽  
Combined Treatment ◽  
Autologous Bone Marrow ◽  
Autologous Bone
Sign in / Sign up

Export Citation Format

Share Document